INT'L GROUP(SZ:000411)2016-04-15 16:00Financial Performance - The company's operating revenue for 2015 was CNY 15,466,436,916.07, representing a 9.90% increase compared to CNY 14,073,811,135.61 in 2014[17]. - The net profit attributable to shareholders for 2015 was CNY 68,758,646.51, a 5.06% increase from CNY 65,447,137.92 in 2014[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 65,938,026.03, up 10.59% from CNY 59,622,294.01 in 2014[17]. - The net cash flow from operating activities was CNY 94,336,215.49, an increase of 7.14% compared to CNY 88,049,363.70 in 2014[17]. - The total assets at the end of 2015 were CNY 6,124,973,797.98, a 17.54% increase from CNY 5,211,120,731.96 at the end of 2014[17]. - The net assets attributable to shareholders at the end of 2015 were CNY 673,957,432.77, reflecting a 10.77% increase from CNY 608,427,136.37 at the end of 2014[17]. - The basic earnings per share for 2015 were CNY 0.33, a 3.13% increase from CNY 0.32 in 2014[17]. - The diluted earnings per share for 2015 were also CNY 0.33, consistent with the basic earnings per share[17]. - The weighted average return on equity for 2015 was 10.72%, down from 11.38% in 2014[17]. - Total revenue for the year was approximately CNY 15.57 billion, with a quarterly breakdown of CNY 3.79 billion, CNY 3.80 billion, CNY 3.94 billion, and CNY 3.93 billion respectively[22]. - Net profit attributable to shareholders for the year was CNY 68.76 million, with quarterly figures of CNY 16.83 million, CNY 18.27 million, CNY 20.15 million, and CNY 13.52 million[22]. Investments and Assets - The company experienced a significant increase in construction in progress, growing by 746.32% compared to the beginning of the year, due to investments in public medical logistics platforms[29]. - Other receivables increased by 132.59% year-on-year, attributed to increased deposits for medical devices and vaccines[29]. - The company has established a comprehensive modern logistics system, with a logistics center area of 60,000 square meters, providing integrated services including storage, logistics processing, and centralized distribution[30]. - The company has a strong market presence, achieving over 70% coverage in grassroots medical institutions and expanding its distribution network through acquisitions of regional subsidiaries[30]. - The company is actively developing e-commerce, with its subsidiary operating a B2C platform and enhancing service offerings through online transactions[31]. - The company reported a government subsidy income of CNY 11.76 million for the year, down from CNY 13.33 million in the previous year[24]. - The company has partnerships with 40 of the top 50 pharmaceutical companies globally, ensuring a diverse product range and high medication availability in medical institutions[31]. - The company aims to enhance its position as a leading pharmaceutical service provider in China, focusing on modern logistics and third-party logistics services[32]. - The company has initiated a major asset restructuring plan to streamline its equity structure and enhance sustainable development[36]. - The company has established a long-term development plan for 2016-2025, focusing on energy conservation and cost control initiatives[36]. Financial Management and Strategy - The company successfully issued short-term financing bonds amounting to ¥500 million in September 2015, effectively reducing financial costs[36]. - The company reported a 79.34% decrease in investment income, primarily due to the previous year's gains from the disposal of equity in joint ventures[39]. - The company achieved a gross margin of 5.44% in the pharmaceutical sales sector, with a slight decrease of 0.20% compared to the previous year[45]. - The company reported a total investment of 203,599,338.17 CNY for the reporting period, which is a 33.25% increase from the previous year's investment of 152,800,560.34 CNY[65]. - The total cash inflow from financing activities increased by 36.93% to 4,196,728,102.69 CNY, primarily due to increased borrowings and cash from issuing short-term financing bonds[57]. - The company plans to issue short-term financing bonds not exceeding 500 million to optimize financing structure and support subsidiaries[126]. - The company’s chairman signed a joint statement to stabilize investor confidence and committed to not reducing shareholdings within the year[127]. - The company plans to continue with entrusted loan programs in the future[122]. - The company is focused on improving its supply chain financial optimization projects to lower financial expenses and increase sales profits[80]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential deals[162]. Corporate Governance and Compliance - The company has conducted 6 investor meetings with 48 institutions and 5 individuals during the reporting period[85]. - The cash dividend policy has been revised to ensure compliance with regulations and protect minority shareholders' rights[88]. - The company did not distribute any cash dividends in 2015, maintaining a 0.00% payout ratio[91]. - The company has committed to not reducing its stock holdings in 2015 and plans to actively buy back shares[94]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[95]. - The company has maintained an independent governance structure, ensuring no significant discrepancies with regulatory requirements[180]. - The company’s annual shareholder meeting had a participation rate of only 0.04%, indicating low investor engagement[184]. - The audit committee held two meetings during the reporting period to review the 2014 annual financial report and the appointment of the auditing firm for 2015[190]. - The company has no significant related party transactions related to daily operations during the reporting period[105]. - The company has no stock incentive plans or employee stock ownership plans in place during the reporting period[104]. Social Responsibility and Community Engagement - The company actively engages in social responsibility activities, including a blood donation campaign where 38 employees donated 10,700 milliliters of blood[134]. - The company is committed to fulfilling its social responsibilities through various charitable activities, including support for disabled individuals and educational initiatives[133]. - The company has a comprehensive training program focusing on key positions and employee development, enhancing competitiveness in the market[176]. Human Resources and Management - The total number of employees in the company is 2,002, with 856 in sales and 153 in finance[173]. - The total compensation for directors, supervisors, and senior management during the reporting period amounts to 938.19 thousand yuan[172]. - The company has 67 employees with a master's degree or above, and 663 with a bachelor's degree[174]. - The company has a total of 246 employees in its main subsidiaries[173]. - The company has no production personnel, indicating a focus on sales and administrative roles[174]. - The company has 468 administrative personnel and 525 in other roles such as storage and transportation[174]. - The company implemented a salary policy linked to performance, enhancing efficiency in resource allocation to high-performing departments and strategic business areas[176]. Audit and Financial Reporting - The audit opinion type is a standard unqualified opinion[200]. - The audit report was signed on April 14, 2016[200]. - The financial statements audited include the balance sheet as of December 31, 2015, and the income statement for the year 2015[200]. - The audit was conducted by Tianzhi International Accounting Firm[200]. - The report was signed by registered accountants Hu Jianjun, Ha Changhong, and Yao Lu[200]. - The audit report number is Tianzhi Audit No. [2016]4791[200]. - The financial statements include cash flow statements and changes in equity statements[200]. - The company has no significant competition with its controlling shareholder, maintaining operational independence[181]. - The internal control evaluation report indicated that 97.17% of the total assets and 95.04% of the total revenue were included in the evaluation scope[194]. - There were no significant internal control deficiencies identified during the reporting period[196].